MyAverix Finance MyAverix Finance

STU

TG Therapeutics Inc (NKB2)

TG Therapeutics Inc (NKB2) is listed on STU. As of 2026-03-24, reported P/E ratio is 18.00. Use this page for a quick overview, then open the MyAverix Finance app for income statements, balance sheet, cash flow, and news.

Data as of 2026-03-24

Download on the App Store Get it on Google Play

Download free on iPhone and Android

Key metrics for NKB2

P/E ratio
18.00

TG Therapeutics Inc (NKB2) — FAQ

What is NKB2's P/E ratio?

The price-to-earnings (P/E) ratio for TG Therapeutics Inc (NKB2) is 18.00 (data as of 2026-03-24).

Does TG Therapeutics Inc pay a dividend?

Dividend yield is not available in the current snapshot for TG Therapeutics Inc (NKB2). Check the MyAverix Finance app for the latest dividend data.

What exchange is NKB2 listed on?

NKB2 is listed on STU.

Full report in the app

Get the full report in the MyAverix Finance app — income, balance sheet, cash flow, ratios, and multi-year trends in one place.

← All stocks

MyAverix Finance provides company information and financial data for educational and research purposes only. We are not a broker, advisor, or investment service. Data may be delayed or incomplete. Past performance does not guarantee future results. Always do your own research before making financial decisions.

Terms of Use

App Store Google Play